Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.

Clinical human genetic studies have recently identified the tetrodotoxin (TTX) sensitive neuronal voltage gated sodium channel Nav1.7 (SCN9A) as a critical mediator of pain sensitization. Herein, we report structure-activity relationships for a novel series of 2,4-diaminotriazines that inhibit hNav1.7. Optimization efforts culminated in compound 52, which demonstrated pharmacokinetic properties appropriate for in vivo testing in rats. The binding site of compound 52 on Nav1.7 was determined to be distinct from that of local anesthetics. Compound 52 inhibited tetrodotoxin-sensitive sodium channels recorded from rat sensory neurons and exhibited modest selectivity against the hERG potassium channel and against cloned and native tetrodotoxin-resistant sodium channels. Upon oral administration to rats, compound 52 produced dose- and exposure-dependent efficacy in the formalin model of pain.

[1]  D. Price,et al.  Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain. , 2011, European journal of pain.

[2]  V. Warren,et al.  Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. , 2010, Bioorganic & medicinal chemistry letters.

[3]  A. Malmberg,et al.  Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain , 2010, PAIN®.

[4]  R. Dworkin,et al.  Treatment of neuropathic pain: an overview of recent guidelines. , 2009, The American journal of medicine.

[5]  K. Lyons,et al.  Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain. , 2009, Bioorganic & medicinal chemistry letters.

[6]  K. Lyons,et al.  Discovery of a novel class of isoxazoline voltage gated sodium channel blockers. , 2009, Bioorganic & medicinal chemistry letters.

[7]  E. Nielsen,et al.  Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3′-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[8]  Matthew S. Johnson,et al.  Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. , 2008, Bioorganic & medicinal chemistry.

[9]  V. Warren,et al.  3-Amino-1,5-benzodiazepinones: potent, state-dependent sodium channel blockers with anti-epileptic activity. , 2008, Bioorganic & medicinal chemistry letters.

[10]  V. Warren,et al.  Imidazopyridines: a novel class of hNav1.7 channel blockers. , 2008, Bioorganic & medicinal chemistry letters.

[11]  Matthew S. Johnson,et al.  Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. , 2008, Journal of medicinal chemistry.

[12]  Clare London,et al.  Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. , 2007, Biochemistry.

[13]  D. Macintyre,et al.  Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. , 2007, Bioorganic & medicinal chemistry letters.

[14]  P. Lund,et al.  A stop codon mutation in SCN9A causes lack of pain sensation. , 2007, Human molecular genetics.

[15]  D. Macintyre,et al.  Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. , 2007, Bioorganic & medicinal chemistry letters.

[16]  E. Sellers,et al.  An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. , 2007, Journal of pain and symptom management.

[17]  M. Dubé,et al.  Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.

[18]  K. Longenecker,et al.  Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors. , 2007, Journal of medicinal chemistry.

[19]  J. Schulz,et al.  Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain. , 2007, Bioorganic & medicinal chemistry letters.

[20]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[21]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[22]  E. Stevens,et al.  The role of sodium channels in neuropathic pain. , 2006, Seminars in cell & developmental biology.

[23]  A. Termin,et al.  Small Molecule Blockers of Voltage‐gated Sodium Channels , 2006 .

[24]  S. McMahon,et al.  Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice , 2006, Molecular pain.

[25]  R. L. Kirby,et al.  SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. , 2005, The Journal of investigative dermatology.

[26]  M. Fisher,et al.  Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain. , 2005, Bioorganic & medicinal chemistry letters.

[27]  G. Wang,et al.  Interactions of Local Anesthetics with Voltage-gated Na+ Channels , 2004, The Journal of Membrane Biology.

[28]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[29]  Stephen G. Waxman,et al.  International Union of Pharmacology. XXXIX. Compendium of Voltage-Gated Ion Channels: Sodium Channels , 2003, Pharmacological Reviews.

[30]  G. Wang,et al.  Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. , 2003, Cellular signalling.

[31]  T. Yaksh,et al.  An automated flinch detecting system for use in the formalin nociceptive bioassay. , 2001, Journal of applied physiology.

[32]  W. Catterall,et al.  Interaction of batrachotoxin with the local anesthetic receptor site in transmembrane segment IVS6 of the voltage-gated sodium channel. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Swartz,et al.  Inhibition of calcium channels in rat central and peripheral neurons by omega-conotoxin MVIIC , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  B. Bean,et al.  Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. , 1994, Molecular pharmacology.

[35]  G. B. Brown,et al.  3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  B. Katzung,et al.  Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. , 1977, Biochimica et biophysica acta.

[37]  B. Hille,et al.  Local anesthetics: hydrophilic and hydrophobic pathways for the drug- receptor reaction , 1977, The Journal of general physiology.

[38]  A. Wickenden,et al.  Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. , 2009, Combinatorial chemistry & high throughput screening.

[39]  A. L. Goldin,et al.  Resurgence of sodium channel research. , 2001, Annual review of physiology.

[40]  W. Catterall.  Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. , 1980, Annual review of pharmacology and toxicology.

[41]  W. Catterall,et al.  Interaction of polypeptide neurotoxins with a receptor site associated with voltage-sensitive sodium channels. , 1980, Journal of supramolecular structure.